KRAS and neoplasm: Consistent with the results using the KRAS-mutated CRC cell lines, the combined effects of KYA1797K and cetuximab on the growth inhibition were not observed in the tumor organoids derived from the small intestinal tumor cells of ApcMin/+/KrasG12DLA2 mice.